A Preliminary Study for the Development of Clinical Practice Guidelines of Korean Medicine for Bladder Cancer

방광암(膀胱癌)의 한의학적 진료지침 개발을 위한 기초 연구

  • Park, Tae-yeol (Kyeongin Korean Medicine Clinic) ;
  • Yoo, Hwa-seong (East West Cancer Center, Dunsan Korean Medicine Hospital of Dae-Jeon University) ;
  • Lee, Sang-hun (Dept. of Medical Consilience, Graduate School, Dan-Kook University)
  • 박태열 (경인한의원) ;
  • 유화승 (대전대학교 둔산한방병원 동서암센터) ;
  • 이상헌 (단국대학교 대학원 생명융합학과)
  • Received : 2016.09.06
  • Accepted : 2016.11.23
  • Published : 2016.12.30


Objectives: This study presents Korean medicine clinical practice guidelines for bladder cancer, of which the 5-year survival rate has still been about 75% since the 1990s despite the rapid development of medical science. Methods: A consensus was reached by an expert committee composed of professors and researchers who specialize in Korean medicine on the basis of a literature review that included other countries' clinical guidelines and a textbook. Results: Traditional Chinese medicine clinical practice guidelines were published for the first time in 2014. In Korea, the medical system is different from China in that Korea has completely dualized Korean and Western medicine and a low availability of proprietary herbal medicines. Therefore, these Korean medicine clinical practice guidelines for treating bladder cancer based on the previously published guidelines of Chinese medicine will help first-line Korean medicine doctors. Conclusions: Further studies related to Korean medicine are necessary to develop more advanced Korean medicine clinical practice guidelines for treating bladder cancer.


Supported by : 한국보건산업진흥원


  1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27(3):289-93.
  2. Kiemeney LA, Lemmers FA, Verhoeven RH, Aben KK, Honing C, de Nooijer J, et al. The risk of cancer in the Netherlands. Nederlands tijdschrift voor geneeskunde 2008;152(41):2233-41.
  3. 중앙암등록본부 보. 국가암등록사업 연례보고서 (2012년 암등록통계). 보건복지부 중앙암등록본부 2014.
  4. Zeng C, Wen W, Morgans AK, Pao W, Shu XO, Zheng W. Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. JAMA oncology 2015;1(1):88-96.
  5. 중앙암등록본부 보. 국가암등록사업 연례 보고서(2006년 암발생, 1993-2006년 암생존 현황). 보건복지부 중앙암등록본부 2009.
  6. 허준. 원본 동의보감 신증판. 서울: 남산당; 2014.
  7. 홍원식 역. 황제내경소문. 서울: 전통문화연구회; 1992.
  8. 趙紅星. 中藥運用對膀胱癌介入化療術后不良反應的影響. 中華中医藥學刊 2013;10.
  9. 鄒鹏, 趙紅. 非肌層浸潤性膀胱癌的中西医治療硏究进展. 亞太傳統医藥 2015;01.
  10. 馬成杰, 李忠. 膀胱癌的中西医結合診治. 中國臨床医生 2007;05.
  11. 朱剑勇, 童炎岳, 万里軍, 祝秀文. 中医藥輔助治療對膀胱癌術后患者生存質量的影響. 遼宁中医雜志 2013;09.
  12. 曾曄, 賴海標, 鐘亮, 黃智峰, 吳松, 李森, et al. 中西医結合治療淺表性膀胱癌30例. 中医硏究 2009;05.
  13. Park T, Lee S. Clinical Experiences of Korean Medicine Treatment against Urinary Bladder Cancer in General Practice. Evidence-based complementary and alternative medicine : eCAM 2016;2016:3759069.
  14. Network NCC. Bladder Cancer (NCCN Guidelines). 2015.
  15. Cancer NCCf. Bladder cancer: diagnosis and management. 2015.
  16. 대한비뇨기종양학회. 방광암 진료지침. 대한비뇨기종양학회 2005.
  17. 林洪生. 惡性腫瘤中醫診療指南. 北京: 人民衛生出版社; 2014, p. 521-39.
  18. Lee MS. Recommendations for Development of Clinical Practice Guideline in Korean Medicine (PRIDE-CPG-KM). Korea Institute of Oriental Medicine 2013.
  19. Kogevinas M, 't Mannetje A, Cordier S, Ranft U, Gonzalez CA, Vineis P, et al. Occupation and bladder cancer among men in Western Europe. Cancer Cause Control 2003;14(10):907-14.
  20. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association Between Smoking and Risk of Bladder Cancer Among Men and Women. Jama-J Am Med Assoc 2011;306(7):737-45.
  21. 郭文鹏, 戎志斌, 尚業. "膀胱癌濕热瘀毒蕴積病因病机与其有氧糖酵解代謝异常相關" 假設的提出. 环球中医藥 2015;01:59-62.
  22. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000;163(2):524-7.
  23. Satoh E, Miyao N, Tachiki H, Fujisawa Y. Prediction of muscle invasion of bladder cancer by cystoscopy. Eur Urol 2002;41(2):178-81.
  24. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61(1):109-18; discussion 18.
  25. Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int 2011;108(7):1119-23.
  26. Datta SN, Allen GM, Evans R, Vaughton KC, Lucas MG. Urinary tract ultrasonography in the evaluation of haematuria-a report of over 1,000 cases. Annals of the Royal College of Surgeons of England 2002;84(3):203-5.
  27. Herr HW. Routine CT scan in cystectomy patients: does it change management? Urology 1996;47(3):324-5.
  28. Tekes A, Kamel I, Imam K, Szarf G, Schoenberg M, Nasir K, et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR American journal of roentgenology 2005;184(1) :121-7.
  29. Apolo AB, Riches J, Schoder H, Akin O, Trout A, Milowsky MI, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(25):3973-8.
  30. Epstein JI EJ, Sesterhenn I, Sauter G. World Health Organization Classification of Tumors. IARC Press 2004.
  31. Lagwinski N, Thomas A, Stephenson AJ, Campbell S, Hoschar AP, El-Gabry E, et al. Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. The American journal of surgical pathology 2007;31(12):1777-87.
  32. Grignon DJ, Ro JY, Ayala AG, Johnson DE, Ordonez NG. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991;67(8):2165-72.<2165::AID-CNCR2820670827>3.0.CO;2-M
  33. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, Editor. AJCC Cancer Staging Manual. Chicago: Springer; 2010.
  34. Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol 2014;191(1) :40-7.
  35. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64(4):639-53.
  36. Miladi M, Peyromaure M, Zerbib M, Saighi D, Debre B. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 2003;43(3):241-5.
  37. Dalbagni G, Vora K, Kaag M, Cronin A, Bochner B, Donat SM, et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 2009;56(6) :903-10.
  38. Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder cancer. Research and reports in urology 2015;7:65-79.
  39. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008;53(4):709-19.
  40. Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ, et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007;177(4):1283-6; discussion 6.
  41. Grossman HB, Stenzl A, Moyad MA, Droller MJ. Bladder cancer: chemoprevention, complementary approaches and budgetary considerations. Scandinavian journal of urology and nephrology. Supplementum 2008(218):213-33.
  42. Lee RK, Abol-Enein H, Artibani W, Bochner B, Dalbagni G, Daneshmand S, et al. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int 2014;113(1):11-23.
  43. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(16):2171-7.
  44. Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 2014;66(1):42-54.
  45. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. The New England journal of medicine 2012;366(16):1477-88.
  46. Pal SK, Milowsky MI, Plimack ER. Optimizing systemic therapy for bladder cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2013;11(7):793-804.
  47. Asgari MA, Safarinejad MR, Shakhssalim N, Soleimani M, Shahabi A, Amini E. Quality of life after radical cystectomy for bladder cancer in men with an ileal conduit or continent urinary diversion: A comparative study. Urology annals 2013;5(3):190-6.
  48. Perez-Jacoiste Asin MA, Fernandez-Ruiz M, Lopez-Medrano F, Lumbreras C, Tejido A, San Juan R, et al. Bacillus Calmette-Guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine 2014;93(17):236-54.
  49. 彭蕴茹, 沈明勤, 罗宇慧, 叶其正, 石磊, 王志刚.金匮腎气丸防治小鼠腎陽虚的實驗硏究. 中成藥 2004;05:395-7.
  50. 韓磊, 宋艶麗. 知柏地黄丸的藥理作用和臨床應用硏究進展. 中國藥房 2012;15:1430-2.
  51. 张颖, 张瑞菊. 八珍湯抗腫瘤及補气血的藥理臨床硏究進展. 現代中西医結合雜志 1998;12:1876-7.
  52. 沈先東, 胡順金, 任克軍, 吳俊. 八珍湯治療腫瘤相關性貧血療效觀察. 中医藥臨床雜志 2010;05:401-3.
  53. 劉雅, 張海港, 張翼冠, 張皓月, 李皢輝. 当歸補血湯對气虛血瘀大鼠免疫功能及相關基因的調控. 中藥藥理与臨床 2009;05:10-3.
  54. 郭剛, 許建華. 十全大補湯抑制腫瘤侵襲, 轉移的硏究概述. 环球中医藥 2011;01:74-6.
  55. 劉群英. 補中益气湯治療脾虚証作用机制硏究. 現代中西医結合雜志 2011;07:799-804.
  56. 李濱, 齊鳳琴, 李燕敏, 劉石磊. 補中益气湯抗腫瘤作用的實驗硏究. 中医藥學报 2006;01:22-3.
  57. 王蕾, 李娟. 針刺加補中益气湯治療婦科術后膀胱麻痹30例体會. 中國鄕村医藥 2006;12:49-50.
  58. 賈瑞明, 宋俊生. 旋覆代赭湯及其加减方預防腫瘤化療后惡心嘔吐臨床隨机對照試驗的Meta分析. 吉林中医藥 2010;03:218-9.
  59. 史國軍, 山广志, 王海榮, 董晶, 楊華锋. 旋覆代赭湯加味防治腫瘤化療后惡心嘔吐隨机對照試驗的 Meta分析. 中華腫瘤防治雜志 2011;23:1881-4.
  60. 賈淑麗. 橘皮竹茹湯治療腫瘤化療的消化反應58例療效觀察. 中医臨床硏究 2011;13:46-8.
  61. 王羽, 王佩, 趙九紅. 中西医結合預防化療引起消化道反應86例臨床觀察. 四川中医 2007;08:73-4.
  62. 游向前. 中西医結合預防腫瘤化療所致臨吐98例. 中國中西医結合雜志 2003;10:785-7.
  63. 張弦. 八珍湯治療惡性腫瘤放, 化療后骨髓抑制30例臨床觀察. 湖南中医雜志 2013;04:51-3.
  64. 李宝鴻, 廉南. 加味当歸補血湯對腫瘤患者放化療增效减毒作用的臨床觀察附:392例病例報告. 成都中医藥大學學報 2005;02:7-9.
  65. 張梅榮, 李冬云, 張寅, 陳信義. 加味当歸補血湯預防化療所致白细胞减少的臨床觀察. 中國中藥雜志 2006;20:174-7.
  66. 王一安. 十全大補湯加减防治化療毒副反癄70例臨床觀察. 浙江中医雜志 2011;08:576.
  67. 鄭建軍, 吳新華, 張再躍, 王磊. 十全大補湯對腫瘤患者放化療减毒作用的觀察. 山東中医雜志 2000; 07:395-6.
  68. 齋聪. 十全大補湯减輕化療副作用的臨床与實驗觀察. 浙江中医學院學報 2000;04:16-8.
  69. 趙益, 羅蓉, 朱衛丰, 尚广彬, 徐國良, 劉紅宁. 六味地黄丸對腫瘤細胞抑制作用的硏究. 中藥新藥与臨床藥理 2011;06:598-602.
  70. 夏清山, 張旭升. 六味地黄丸在化療中增效减毒作用的臨床觀察. 湖北中医雜志 2005;11:14-5.
  71. Guo Z, Jia X, Liu JP, Liao J, Yang Y. Herbal medicines for advanced colorectal cancer. Cochrane Database Syst Rev 2012;5:CD004653.
  72. Su CX, Wang LQ, Grant SJ, Liu JP. Chinese herbal medicine for cancer-related fatigue: a systematic review of randomized clinical trials. Complementary therapies in medicine 2014;22(3) :567-79.
  73. Li SG, Chen HY, Ou-Yang CS, Wang XX, Yang ZJ, Tong Y, et al. The Efficacy of Chinese Herbal Medicine as an Adjunctive Therapy for Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis. Plos One 2013;8(2):e57604.
  74. 李东芳, 陶煉. 芍藥湯加减治療急性放射性直腸炎36例. 四川中医 2002;04:47.
  75. 李爱苓, 孫建衡, 晁紅霞, 王桂香. 子宫經癌放射治療致放射性膀胱炎378例臨床分析. 中華婦產科雜志 1995;12:741-3.
  76. 吳玉生. 常見腫瘤病中西醫診療與調養. 广州: 廣東旅游出版社; 2002, p. 186-7.
  77. van Osch FH, Jochems SH, van Schooten FJ, Bryan RT, Zeegers MP. Significant role for lifetime cigarette smoking in worsening bladder cancer and upper tract urothelial carcinoma prognosis: a meta-analysis. J Urol 2015.